Highlights
NCI invites input from the scientific community regarding Translational Research Opportunities that follow the Immune Response Modifiers Pathway to testing in Phase I/II clinical trials. All members of the scientific community, including investigators from academic, non-academic, pharmaceutical industry, and clinical oncologists are encouraged to respond to this creative new approach to accelerate translational research. Responses will be accepted through August 24, 2009.
The proposed START (Standard Terms of Agreement for Research Trial) clauses are designed to reduce the time spent on contract negotiations between pharmaceutical/biotech companies and academic medical centers.
The purpose of the program is to establish a comprehensive database containing regularly updated information on all NCI funded interventional clinical trials. Grantees will be requested to enter specific information about each clinical trial into the database. NCI will use this information to coordinate research efforts to optimize our nation's investment in cancer research.
CCCT Programs
The Clinical Trials Working Group (CTWG) was established to recommend ways to enhance the NCI's Clinical Trials Enterprise. CCCT oversees implementation of the resulting 22 recommendations which now guide the Institute's efforts to streamline and strengthen its clinical research enterprise.
NCI established the Translational Research Working Group (TRWG) to analyze the NCI's investment in translational research and envision its future. Implementation of the resulting 15 initiatives, as coordinated through CCCT, is designed to complement and extend the work of the CTWG by integrating aspects of NCI-funded translational science into a national, coordinated, and collaborative research enterprise that expedites clinical testing of promising basic research.
